On Jun 27, 2018 25.22 % to Target, Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Buy Rating Kept by B. Riley FBR.

June 27, 2018 - By Alice Reed

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Corporate Logo

During Q1 2018 the big money sentiment decreased to 1.02. That’s change of 0.07, from 2017Q4’s 1.09. 29 investors sold all, 96 reduced holdings as Jazz Pharmaceuticals plc ratio dropped. 84 increased holdings while 44 funds amassed holdings. Funds hold 51.95 million shares thus 1.94% less from 2017Q4’s 52.98 million shares.

Balyasny Asset Mngmt Limited Liability Company invested in 153,107 shs or 0.1% of the stock. Victory Capital Management has invested 0% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Andra Ap has invested 0.16% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Invesco holds 231,839 shs. Brinker Inc reported 0.03% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). First Personal Financial Services has 0% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Raymond James Financial Advsr Incorporated invested 0.01% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Adage Cap Prns Group Inc Limited Liability Com invested in 0.12% or 349,189 shs. Pnc Fincl Ser Grp, Pennsylvania-based fund reported 11,321 shs. 3,730 were reported by Sumitomo Mitsui Asset Mngmt Limited. Whittier Trust Com has invested 0% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Kbc Gru Nv invested 0.18% of its capital in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Bank Of America Corp De reported 213,531 shs stake. Assetmark invested in 0% or 3 shs. Bridges Mgmt reported 1,465 shs stake.

Jazz Pharmaceuticals plc registered $5.86 million net activity with 0 buys and 23 selling transactions since January 12, 2018. On Friday, May 11 WILSON KAREN J also sold $620,400 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Young Matthew P. sold $106,512 worth of stock or 700 shs. On Friday, June 1 the insider COZADD BRUCE C sold $1.18 million. Treacy Paul also sold $122,446 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Thursday, March 1.

Reiterated Jazz Pharmaceuticals (NASDAQ:JAZZ) Rating.

Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock Buy rating was kept by B. Riley FBR on Tuesday, 26 June. The broker’s Analysts have a $219 target and would suggest a potential upside of 25.22 % on the stock.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Coverage

In total 11 analysts cover Jazz Pharmaceuticals (NASDAQ:JAZZ). “Buy” rating has 10, “Sell” are 0, while 1 are “Hold”. (NASDAQ:JAZZ) has 91% bullish analysts. 19 are the (NASDAQ:JAZZ)’s ratings reports on Jun 27, 2018 according to StockzIntelligence Inc. On Friday, March 9 the firm earned “Buy” rating by FBR Capital. On Friday, March 23 the firm has “Hold” rating given by H.C. Wainwright. On Monday, June 25 the stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has “Buy” rating given by FBR Capital. On Tuesday, February 20 the company was maintained by Bank of America. In Thursday, April 12 report Piper Jaffray maintained it with “Buy” rating and $20100 target. In Wednesday, February 28 report BMO Capital Markets maintained it with “Outperform” rating and $199 target. The stock rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, January 2. On Wednesday, February 28 the firm earned “Buy” rating by Cantor Fitzgerald. On Monday, May 7 the firm has “Buy” rating given by Cantor Fitzgerald. In Friday, April 6 report Seaport Global maintained it with “Buy” rating and $17500 target.

JAZZ is hitting $174.885 during the last trading session, after increased 0.57%.Currently Jazz Pharmaceuticals plc is uptrending after 8.53% change in last June 27, 2017. JAZZ has 127,093 shares volume. JAZZ underperformed the S&P500 by 4.04%.

On August, 14 WallStreet expected Jazz Pharmaceuticals plc (NASDAQ:JAZZ)’s earnings report, according to Faxor. EPS of $2.87 is 66.86 % up from 2017’s $1.72 EPS. If EPS of $2.87 is reported the profit of JAZZ could hit $173.02M giving it 15.23 P/E. 9.13 % EPS growth is what analysts predict. $2.63 EPS was reported for last quarter.

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally.The company has $10.54 billion market cap. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.23.95 is the P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

A couple more Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news were brought out by: Prnewswire.com which released on June 06, 2018 “Jazz Pharmaceuticals to Present at the Goldman Sachs Global Healthcare Conference”, also Streetinsider.com on June 27, 2018 brought out “Jazz Pharmaceuticals (JAZZ) PT Raised to $220 at Cowen; ‘Transitioning Growth Asset'”, the next Benzinga.com is “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” on June 21, 2018. Seekingalpha.com has article titled “Key events next week – healthcare”.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.